

Scientific letter

High-flow Nasal Oxygen Therapy Yields a Favorable Outcome in Patient Presenting With Kussmaul Breathing



La oxigenoterapia nasal de alto flujo produce un resultado favorable en pacientes que presentan respiración de Kussmaul

Dear Editor,

Kussmaul breathing is a form of hyperventilation linked to metabolic acidosis, and is a compensatory attempt to decrease the CO₂ in the blood via elimination through the lungs. Kussmaul breathing is generally well tolerated, provided the cause is effectively managed. However, some respiratory complications induced by the increased ventilatory demand have been described, with respiratory muscle fatigue being the most critical.¹ Occasional incidences of pneumothorax and pneumomediastinum have also been reported.²

There is no specific treatment for Kussmaul breathing other than addressing the underlying metabolic problem and providing ventilatory support if respiratory fatigue occurs. Similar to acidemia induced by acute respiratory acidosis, dyspnea in acidemia engendered by metabolic acidosis can be described as “air hunger.” We recently observed this in an 81-year-old man with ischemic heart disease and renal failure caused by nephrolithiasis who was hospitalized because significant metabolic decompensation. He appeared very dyspneic, with regular hyperpnea – characteristic of Kussmaul breathing – but with an oxygen saturation of 92% on room air and respiratory rate close to 40 breaths/min. An arterial blood gas analysis revealed metabolic acidosis with an elevated anion gap attributed to the considerably elevated blood urea nitrogen levels (Table 1). Because an elevated alveolar to arterial oxygen gradient, the resident physician placed him on high-flow oxygen therapy (HFOT) via a nasal cannula, with an F_IO₂ of 50% and a flow rate of 60 L/min. A few minutes after commencing HFOT, the patient was breathing more comfortably, with less distress,

and in a more superficial respiratory pattern; his respiratory rate decreased to 28 breaths/min. However, a control arterial blood gas analysis performed 4 h into the HFOT showed that the acidotic profile persisted. That is, the patient exhibited the same hyperventilation anomaly but with less respiratory work. His respiratory situation and metabolic acidosis persisted for the next two days; subsequently, with adjustments to the administered parenteral solutions, he was eventually able to regain adequate metabolic control and was finally weaned off HFOT.

A physiological effect of HFOT is a reduction in CO₂ levels due to a washing-out effect in the airways that lowers CO₂ rebreathing and functional dead space. In healthy subjects, this resulting decrease in CO₂ levels is not as evident as in COPD patients with some degree of hypercapnia. However, an HFOT-induced decrease in minute volume is typically unaccompanied by a proportional increase in CO₂ levels.³ Similarly, in patients with sepsis, increased respiratory drive and inspiratory effort induced by lactic acidosis are effectively modulated by HFOT without CO₂ elevation.⁴ In our patient, we surmise that the HFOT maintained compensatory alveolar hyperventilation, with the advantage of abolishing Kussmaul breathing and the accompanying increased respiratory workload. The recommendations for treating respiratory distress in these cases are based on diabetic ketoacidosis guidelines. In diabetic ketoacidosis, HFOT is accepted as a very useful and safe alternative to removing CO₂ and reducing dead space while facilitating compensation for metabolic acidosis.⁵

The use of HFOT is rapidly increasing in various clinical situations, but this is occurring without clear indications or clinical practice guidelines. Effects of HFOT on arterial blood gas parameters especially partial CO₂ require further investigation to provide insight into the efficacy and safety of the treatment. We observed in the present case how HFOT can be beneficial while waiting to resolve the metabolic issue inducing Kussmaul breathing; it makes the hyperventilation – which is necessary for compensatory elimination of CO₂ – more bearable and lowers the respiratory workload and risk of complications.

Table 1

Four-day follow-up on arterial blood gas determinations.

Day	1	1 (4 h)	2	3	4
pH	7.34	7.36	7.39	7.4	7.42
PaO ₂ (mmHg)	68	98	90	94	88
PaCO ₂ (mmHg)	17	21	21	23	26
HCO ₃ (mEq/L)	9.4	12.4	12.7	14.6	18.4
Lactate (mmol/L)	1.2	1.4	1.0	0.9	1.0
Creatinine (mg/dL)	5.16	–	4.9	4.14	4.06
BUN (mg/dL)	93.9	–	90.5	83	75

The bold values indicate days during which the patient underwent HFOT. BUN: blood urea nitrogen.

Informed consent

Consent was obtained from the patient and family caregivers.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors' contributions

Each of the authors contributed to the planning and writing of the manuscript, and each has read and approved all statements in it.

Conflicts of interests

The authors state that they have no conflict of interests.

References

1. Gallo de Moraes A, Surani N. Effects of diabetic ketoacidosis in the respiratory system. *World J Diabetes*. 2019;10:16–22, <http://dx.doi.org/10.4239/wjd.v10.i1.16>.
2. Soe-Jensen P. Asymptomatic mediastinal and neck emphysema after Kusmaul's respiration and purging. *Ugeskr Laeger*. 2022;184. V03220177.
3. Delorme M, Bouchard PA, Simon M, Simard S, Lellouche F. Physiologic effects of high-flow nasal cannula in healthy subjects. *Respir Care*. 2020;65:1346–54, <http://dx.doi.org/10.4187/respcare.07306>.
4. Mauri T, Spinelli E, Pavlovsky B, Grieco D, Ottaviani I, Basile MC, et al. Effects of high flow nasal cannula on respiratory effort in patients with extra-pulmonary sepsis or septic shock: a sub-phenotypes analysis. *Am J Respir Crit Care Med*. 2021;203:A2775, <http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1.MeetingAbstracts.A2775>.
5. Long B, Willis GC, Lentz S, Koyfman A, Gottlieb M. Evaluation and management of the critically ill adult with diabetic ketoacidosis. *J Emerg Med*. 2020;59:371–83, <http://dx.doi.org/10.1016/j.jemermed.2020.06.059>.

René Agustín Flores-Franco^{a,*}, Carlos Mauricio González-Ponce^b, Victor Irigoyen-Monroy^c

^a Servicio de Neumología, Hospital Christus Muguerza del Parque, Chihuahua, Chih, Mexico

^b Servicio de Terapia Intensiva, Hospital Christus Muguerza del Parque, Chihuahua, Chih, Mexico

^c Servicio de Nefrología, Hospital Christus Muguerza del Parque, Chihuahua, Chih, Mexico

* Corresponding author.

E-mail address: rflores99@prontomail.com (R.A. Flores-Franco).